These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 19375907)

  • 1. Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
    Macefield RC; Lane JA; Metcalfe C; Down L; Neal DE; Hamdy FC; Donovan JL
    Eur J Cancer; 2009 Sep; 45(14):2569-73. PubMed ID: 19375907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
    Brindle LA; Oliver SE; Dedman D; Donovan JL; Neal DE; Hamdy FC; Lane JA; Peters TJ
    BJU Int; 2006 Oct; 98(4):777-82. PubMed ID: 16978272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
    Loeb S; Roehl KA; Antenor JA; Catalona WJ; Suarez BK; Nadler RB
    Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL.
    Canby-Hagino E; Hernandez J; Brand TC; Troyer DA; Higgins B; Ankerst DP; Thompson IM; Leach RJ; Parekh DJ
    Urology; 2007 Oct; 70(4):748-52. PubMed ID: 17991549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested.
    Watson E; Hewitson P; Brett J; Bukach C; Evans R; Edwards A; Elwyn G; Cargill A; Austoker J
    Patient Educ Couns; 2006 Nov; 63(3):367-79. PubMed ID: 16875796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - Results from a prospective, population-based, randomised study.
    Carlsson S; Aus G; Wessman C; Hugosson J
    Eur J Cancer; 2007 Sep; 43(14):2109-16. PubMed ID: 17643983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy.
    Nam RK; Toi A; Trachtenberg J; Klotz LH; Jewett MA; Emami M; Sugar L; Sweet J; Pond GR; Narod SA
    J Urol; 2006 Feb; 175(2):489-94. PubMed ID: 16406978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychological distress and prostate specific antigen levels in men with and without prostate cancer.
    Turner EL; Lane JA; Metcalfe C; Down L; Donovan JL; Hamdy F; Neal D; Vedhara K
    Brain Behav Immun; 2009 Nov; 23(8):1073-8. PubMed ID: 19486654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer.
    Ochiai A; Fritsche HA; Babaian RJ
    Urology; 2005 Oct; 66(4):819-23. PubMed ID: 16230145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer screening in men with a family history of prostate cancer: the role of partners in influencing men's screening uptake.
    Meiser B; Cowan R; Costello A; Giles GG; Lindeman GJ; Gaff CL
    Urology; 2007 Oct; 70(4):738-42. PubMed ID: 17991547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
    Dyche DJ; Ness J; West M; Allareddy V; Konety BR
    J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower urinary tract symptoms and risk of prostate cancer in Japanese men.
    Matsubara A; Yasumoto H; Teishima J; Seki M; Mita K; Hasegawa Y; Yoshino T; Kato M; Usui T
    Int J Urol; 2006 Aug; 13(8):1098-102. PubMed ID: 16903936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
    Sun L; Moul JW; Hotaling JM; Rampersaud E; Dahm P; Robertson C; Fitzsimons N; Albala D; Polascik TJ
    BJU Int; 2007 Apr; 99(4):753-7. PubMed ID: 17244286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
    Connolly D; Black A; Gavin A; Keane PF; Murray LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families.
    Matikainen MP; Schleutker J; Mörsky P; Kallioniemi OP; Tammela TL
    Clin Cancer Res; 1999 Jun; 5(6):1275-9. PubMed ID: 10389909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF; Crawford ED; Kramer BS; Andriole GL; Gelmann EP; Grubb R; Greenlee R; Gohagan JK
    BJU Int; 2007 Apr; 99(4):775-9. PubMed ID: 17223921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer.
    Hammarsten J; Högstedt B
    Eur J Cancer; 2005 Dec; 41(18):2887-95. PubMed ID: 16243513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
    Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
    J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
    Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.